XTX Topco Ltd Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Key Points

• XTX Topco Ltd has acquired a new stake in Enliven Therapeutics, Inc., purchasing 21,849 shares valued at approximately $430,000.
• Institutional investors own 95.08% of Enliven Therapeutics' stock, with significant recent investments from firms like KLP Kapitalforvaltning and Vanguard Group.
• Analysts have positive outlooks for Enliven Therapeutics, with a consensus rating of "Buy" and an average price target of $41.20.

XTX Topco Ltd bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 21,849 shares of the company's stock, valued at approximately $430,000.

Several other hedge funds have also added to or reduced their stakes in ELVN. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Enliven Therapeutics during the 4th quarter valued at $97,000. BNP Paribas Financial Markets bought a new stake in Enliven Therapeutics during the 4th quarter valued at $112,000. Finally, ExodusPoint Capital Management LP bought a new stake in Enliven Therapeutics during the 4th quarter valued at $200,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Up 5.4%

NASDAQ ELVN traded up $1.02 on Wednesday, hitting $19.91. 64,648 shares of the company's stock traded hands, compared to its average volume of 367,135. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03. The firm's 50-day moving average price is $20.76 and its two-hundred day moving average price is $19.94. The firm has a market capitalization of $976.74 million, a PE ratio of -10.35 and a beta of 0.93.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.34, for a total transaction of $135,606.78. Following the completion of the transaction, the chief operating officer directly owned 303,309 shares in the company, valued at approximately $6,169,305.06. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $21.40, for a total transaction of $267,500.00. Following the transaction, the insider owned 965,188 shares of the company's stock, valued at $20,655,023.20. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,751 shares of company stock worth $2,168,325 in the last three months. Company insiders own 25.90% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, June 16th. Finally, The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.